Impact of protease inhibitors and other antiretroviral treatments on acquired immunodeficiency syndrome survival in San Francisco, California, 1987-1996

被引:51
作者
Schwarcz, SK
Hsu, LC
Vittinghoff, E
Katz, MH
机构
[1] San Francisco Dept Publ Hlth, San Francisco, CA 94102 USA
[2] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA
关键词
acquired immunodeficiency syndrome; HIV; HIV protease inhibitors; protease inhibitors; survival;
D O I
10.1093/aje/152.2.178
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The authors assessed temporal trends in acquired immunodeficiency syndrome (AIDS) survival for 15,271 persons in San Francisco, California, diagnosed between 1987 and 1996 with an opportunistic illness included in the 1987 AIDS case definition. Predictors of survival were evaluated for 5,686 persons who were diagnosed between 1993 and 1996 and met the 1993 AIDS case definition. Median survival was 19 months for persons diagnosed between 1987 and 1989, 17 months for persons diagnosed between 1990 and 1992, 15 months for persons diagnosed between 1993 and 1994, and 31 months for persons diagnosed between 1995 and 1996. Decreased mortality was associated with use of antiretroviral therapy without protease inhibitors before AIDS (relative hazard (RH) = 0.88, 95% confidence interval (CI): 0.8, 1.0) and after AIDS (RH = 0.83, 95% CI: 0.7, 0.9) and use of antiretroviral agents with protease inhibitors before AIDS (RH = 0.25, 95% CI: 0.2, 0.3) and after AIDS (RH = 0.36, 95% CI: 0.3, 0.4). Increased mortality was found for persons aged greater than or equal to 40 years (RH = 1.43, 95% CI: 1.3, 1.6), persons initially diagnosed with an opportunistic illness (RH = 1.97, 95% CI: 1.8, 2.2), and homosexual injection drug users (RH = 1.33, 95% CI: 1.2, 1.5). Survival after AIDS has increased. Treatment with antiretroviral agents, particularly protease inhibitors, strongly predicts improved survival.
引用
收藏
页码:178 / 185
页数:8
相关论文
共 69 条
[21]   Survival in HIV-infected patients who have received zidovudine: Comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy [J].
Graham, NMH ;
Hoover, DR ;
Park, LP ;
Stein, DS ;
Phair, JP ;
Mellors, JW ;
Detels, R ;
Saah, AJ ;
Taylor, E ;
Margolick, JB ;
Markham, R ;
McArthur, J ;
Farzadegan, H ;
Armenian, H ;
Chmiel, JS ;
Cohen, B ;
Wesch, J ;
Wolinsky, S ;
Visscher, BR ;
Fahey, JL ;
Giorgi, JV ;
Dudley, J ;
Lee, M ;
Nishanian, P ;
Rinaldo, CR ;
Kingsley, LA ;
Kingsley, A ;
Mellors, J ;
Winkelstein, A ;
Munoz, A ;
Park, L ;
Gange, S ;
Nelson, K ;
Jacobson, LP ;
Su, S .
ANNALS OF INTERNAL MEDICINE, 1996, 124 (12) :1031-1038
[22]  
GRAHAM NMH, 1991, J ACQ IMMUN DEF SYND, V4, P267
[23]   ACCESS TO THERAPY IN THE MULTICENTER AIDS COHORT STUDY, 1989-1992 [J].
GRAHAM, NMH ;
JACOBSON, LP ;
KUO, V ;
CHMIEL, JS ;
MORGENSTERN, H ;
ZUCCONI, SL .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1994, 47 (09) :1003-1012
[24]   Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy [J].
Gulick, RM ;
Mellors, JW ;
Havlir, D ;
Eron, JJ ;
Gonzalez, C ;
McMahon, D ;
Richman, DD ;
Valentine, FT ;
Jonas, L ;
Meibohm, A ;
Emini, EA ;
Chodakewitz, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) :734-739
[25]   A CONTROLLED TRIAL OF EARLY VERSUS LATE TREATMENT WITH ZIDOVUDINE IN SYMPTOMATIC HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION - RESULTS OF THE VETERANS AFFAIRS COOPERATIVE STUDY [J].
HAMILTON, JD ;
HARTIGAN, PM ;
SIMBERKOFF, MS ;
DAY, PL ;
DIAMOND, GR ;
DICKINSON, GM ;
DRUSANO, GL ;
EGORIN, MJ ;
GEORGE, WL ;
GORDIN, FM ;
HAWKES, CA ;
JENSEN, PC ;
KLIMAS, NG ;
LABRIOLA, AM ;
LAHART, CJ ;
OBRIEN, WA ;
OSTER, CN ;
WEINHOLD, KJ ;
WRAY, NP ;
ZOLLAPAZNER, SB .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (07) :437-443
[26]   A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less [J].
Hammer, SM ;
Squires, KE ;
Hughes, MD ;
Grimes, JM ;
Demeter, LM ;
Currier, JS ;
Eron, JJ ;
Feinberg, JE ;
Balfour, HH ;
Dayton, LR ;
Chodakewitz, JA ;
Fischl, MA .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) :725-733
[27]  
HARRIS JE, 1990, JAMA-J AM MED ASSOC, V263, P397, DOI 10.1001/jama.263.3.397
[28]   Decline in deaths from AIDS due to new antiretrovirals [J].
Hogg, RS ;
OShaughnessy, MV ;
Gataric, N ;
Yip, B ;
Craib, K ;
Schechter, MT ;
Montaner, JSG .
LANCET, 1997, 349 (9061) :1294-1294
[29]   Improved survival among HIV-infected individuals following initiation of antiretroviral therapy [J].
Hogg, RS ;
Heath, KV ;
Yip, B ;
Craib, KJP ;
O'Shaughnessy, MV ;
Schechter, MT ;
Montaner, JSG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (06) :450-454
[30]   CLINICAL MANIFESTATIONS OF AIDS IN THE ERA OF PNEUMOCYSTIS PROPHYLAXIS [J].
HOOVER, DR ;
SAAH, AJ ;
BACELLAR, H ;
PHAIR, J ;
DETELS, R ;
ANDERSON, R ;
KASLOW, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (26) :1922-1926